Investorideas.com


Be a guest or sponsor our podcasts - learn more about us : 800 665 0411


Share on StockTwits

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; (CSE: LHS) (OTCQX: LHSIF) (OTCQX: MRMD) (TSX: FAF)

 

Delta, Kelowna, BC - December 3, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2019/120319-StocksToWatch.mp3

Investor Ideas Potcasts, #Cannabis News and #Stocks on the Move; (CSE: LHS) (OTCQX: LHSIF) (OTCQX: MRMD) (TSX: FAF)

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few early announcements.

But first, Shoppers Drug Mart has expanded its online platform for the sale of medical cannabis to include British Columbia, Nova Scotia, Manitoba, Saskatchewan, New Brunswick, P.E.I., Newfoundland and Labrador. The service breaks down existing barriers for patients by providing convenient access to a broader range of options through a single source, alongside expert advice and counsel from trusted healthcare professionals.

According to Statistics Canada, over 1.1 million Canadians use cannabis for medical purposes, but more than 800,000 patients are self-medicating with recreational or illegal cannabis without the guidance of a healthcare professional.i In British Columbia, 18,326 people obtain their medical cannabis through the legal system, but the patient population is likely much larger.ii The high rate of self-medicating is concerning as a 2019 survey found that 76 per cent of medical cannabis patients wrongly believe there are no side effects from combining cannabis with other medications.iii

"Canadians continue to use cannabis for medical purposes but many have been left behind by traditional models. Patients need more convenient access to their medicine with professional oversight and trusted support," said Jeff Leger, President, Shoppers Drug Mart. "We expanded Medical Cannabis by Shoppers™ nationally to provide enhanced service to more patients so they can feel empowered to access medical cannabis through the medical market with the guidance of healthcare professionals."

First launched in Ontario in January 2019 and then in Alberta in April 2019, Medical Cannabis by Shoppers provides patients access to a number of products from Canadian licensed producers, shipped directly and discreetly to their doorstep. Additionally, support is available for patients through the Shoppers cannabis care centre - a call center staffed by professionals who offer counselling and support for patients. Under current regulations, pharmacists cannot dispense medical cannabis from a pharmacy.

Patients in British Columbia can now obtain their medical document (authorization from a health care practitioner) directly from shoppersdrugmart.ca/cannabis or bring it to their local Shoppers Drug Mart pharmacy to help process the information. Specialized advisors from the Shoppers cannabis care centre will then contact patients, review their medical history and any contraindications with current medications, and provide support with online registration and strain selection.

Education for pharmacists is supported by the Shoppers Drug Mart Medical Advisory Board, a panel of independent medical experts from across the country who provide guidance and advice on new clinical evidence, and have developed clinical algorithms to help the Shoppers cannabis care Advisors select the correct strain based on the prescriber's recommendation.

For patients who do not have access to a healthcare practitioner, Shoppers can connect patients to a licensed physician or nurse practitioner to assess whether a patient is an ideal candidate for medical cannabis. Shoppers can connect patients to healthcare practitioners through an online telemedicine portal or patients can use the Shoppers Clinic Finder at https://cannabis.shoppersdrugmart.ca/medical-document-info

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) announced today that it is expanding its product offerings by introducing the G Pen product line of personal, portable devices in all of its dispensaries. G Pen products will be available with Liberty's unique Werc Shop terpene blend.

Grenco Science, the maker of the G Pen Gio, Pro, Connect, Elite and Nova, is a leader in engineering advanced cannabis vaporizers, known for its aesthetics, portability, functionality, and user experience. Grenco Science launched the G Pen in 2012 and was one of the first vaporizer companies to develop a portable device for cannabis concentrates. The G Pen's sleek design and ease of use make it a popular choice among consumers.

"In relationship to our ongoing transformation, Liberty is excited to introduce G Pen's line of world class cannabis vaporizers to our patients who have grown to trust and love the access we offer to the best brands in any category," said Victor Mancebo, Interim Chief Executive Officer of Liberty. "Grenco Science has set the standard for excellence with their user-friendly portable vaporizers."

Chris Folkerts, Founder and CEO Grenco Science said, "Grenco Science is pleased to announce its partnership with Liberty Health Sciences, a leader in Florida's vertically integrated market. We look forward to bringing the G Pen product line to all of Liberty's stores and offering greater accessibility to Florida's medical cannabis consumers."

Liberty's product offerings include eight outstanding quality brands including Liberty Health Sciences, Zentient, Pretty Pistil, Papa's Herb, Mary's Medicinal, PAX, Werc Shop, Lemon and Grass, and is currently working on rolling out nine additional brands, subject to Florida Department of Health approval.

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, announced that the Company has entered into an importation and distribution agreement with Astral Health Ltd., the operating subsidiary of the LYPHE Group Ltd to supply its cannabis-based medicinal products to patients in the United Kingdom under the MHRA 'specials' programme.

"We look forward to the opportunity to provide access to our cannabis-based medicinal formulations to a population and medical community that is seeing increased demand for quality evidence-based products, such as our proprietary research-backed formulations. Both the Astral and Avicanna teams are aligned on the long-term vision and more importantly are qualified to provide the medical community in the United Kingdom with safe, effective and superior cannabinoid-based solutions, education and training," stated Aras Azadian, Chief Executive Officer.

Dean Friday, Chief Executive Officer of LYPHE, commented "We are very proud to be partnering with Avicanna in bringing their products to the UK market. Avicanna are market-leaders in terms of product quality, and their research-backed formulations give the company a distinct advantage in the UK market".

Under the Agreement, Avicanna will supply Astral with CBMPs, and both Avicanna and Astral will work together to achieve key strategic milestones in the United Kingdom related to market activation, market access and safety. The parties will also work together to collaborate on medical education programs with a focus on safety, dose guidance and efficacy. The Agreement will allow Avicanna to begin generating revenue from a growing UK market, while providing patients with increased access to the life-changing medicines they require.

It is expected that the CBMPs will be prepared in Colombia using Avicanna's proprietary research-backed formulations, using cannabis extracts from Santa Marta Golden Hemp S.A.S., a subsidiary of Avicanna, and manufactured at the facilities of Avicanna's exclusive Colombian manufacturer, Altea Farmaceutica S.A. using Good Manufacturing Practices (GMP).

MariMed Inc. (OTCQX: MRMD), a leading multi-state cannabis and hemp operator focused on health and wellness, today announced that its proprietary, in-house brand, Betty's Eddies™, is among the top-selling sublingual and edible products in a national survey conducted by LeafLink, the leading wholesale platform for cannabis products in the United States.

On November 19, LeafLink released its second-annual LeafLink List, honoring the standout cannabis brands, products, and retailers on its B2B e-commerce marketplace, which processes over $1.4B per year in wholesale cannabis orders. Over 1100 brands were included in the survey. MariMed, Inc. in-house brand Betty's Eddies™, which are gluten-free, vegan, and produced with organically grown fruits and veggies, is the LeafLink Winner for Best Selling Medical Product.

MariMed's family of brands sell in the dispensaries it owns and manages, and on a wholesale basis to retailers in each of the six states it operates. Several recent marketing studies have concluded that infused cannabis products will occupy an increasing share of the overall US cannabis market, which according to the 2019 Marijuana Fact Book, is on pace to exceed 35% growth and $12 billion in sales this year.

Betty's is the most widely distributed product in Maryland, reaching over 70 state dispensaries in less than ten months. New SKUs, including Extra Strength Betty's Eddies™, will launch in Maryland, Rhode Island, Illinois, and Massachusetts in December of 2019.

Ryan Crandall, Chief Product Officer and SVP of Sales at MariMed, Inc., said, "I am thrilled cannabis consumers love the Betty's Eddies brand and products as much as our hardworking team, which is responsible for their quality, custom formulation, and wide availability. Betty's will continue to innovate with new seasonal flavors, limited release small-batch drops, and delicious new Betty's products. The expertise to consistently shape the intended product experience in any state or territory is most important to building consumer trust, brand loyalty, and ultimately revenue growth."

The Branded Product Division at MariMed recently launched Betty's Eddies™ in Rhode Island and plans to launch in MA and Puerto Rico in the next 60 days. MariMed will be opening its Panacea Wellness facility in Massachusetts in mid-December for medical cannabis patients, and recently completed the consolidation of its two managed dispensaries in Illinois.

Bob Fireman, CEO of MariMed, Inc., said, "We are pleased to see the strength of our brands recognized for their significant acceptance and sales growth across multiple markets. Our product division is both innovative and highly responsive to tastes, patient needs, and trends that differ from market to market. As our quality manufacturing capacity and licensing relationships grow, we anticipate MariMed's product family to continue to prosper in a crowded market."

Fire & Flower Holdings Corp. (TSX: FAF), will release its financial and operational results for the third quarter ended November 2, 2019 before financial markets open on December 17, 2019.

Fire & Flower's third quarter fiscal 2019 financial and operational results will be available on SEDAR and on the Company's website at https://fireandflower.com/investor-relations.

Following the release of its third quarter fiscal 2019 financial and operational results, Fire & Flower will host a conference call and webcast with Trevor Fencott, Chief Executive Officer at 8:30 AM Eastern Time on December 17, 2019.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns : Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye.

Disclosure: this news article featuring DFLY is a paid for news release on Investorideas.com - third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411



Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories